SPY306.22+0.67 0.22%
DIA256.58+1.31 0.51%
IXIC9,544.02-8.03 -0.08%

JP Morgan Maintains Overweight on Intersect ENT, Lowers Price Target to $18

JP Morgan maintains Intersect ENT (NASDAQ:XENT) with a Overweight and lowers the price target from $28 to $18.

Benzinga · 05/12/2020 15:17

JP Morgan maintains Intersect ENT (NASDAQ:XENT) with a Overweight and lowers the price target from $28 to $18.